Y-Biologics is Korea’s leading R&D biotech company in the field of antibody drug development. Since establishing Y-Biologics in 2007, our company has focused on the research and development of antibody therapeutics, successfully building two main platform technologies: Ymax®-ABL, a unique human antibody library, and ALiCE, a novel format for bispecific T-cell engager antibodies. Utilizing our excellent and differentiated platform technologies, we are striving to become a leading global antibody drug development company in the field of immuno-oncology. Here at Y-Biologics, with our full-cycle antibody development capabilities, we are pursuing full-fledged development of immuno-oncologic drugs using our bispecific antibody platform. We aim to address unmet medical needs by developing a next-generation immunotherapeutics with higher patient response rates and superior efficacy in comparison to existing immuno-oncology drugs.